Dr. Postow Discusses New Targets in Melanoma

Michael A. Postow, MD
Published: Tuesday, Mar 27, 2018



Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses new targets in melanoma.

In the treatment of patients with melanoma, well known targets such as CTLA4 and PD-1 have been at the forefront of research. Ipilimumab (Yervoy) has been shown to successfully target CTLA-4, while pembrolizumab (Keytruda) and nivolumab (Opdivo) target PD-1. But, Postow says that new immunotherapy targets are emerging in 2018.

IDO and LAG-3 both have very interesting emerging data in melanoma, says Postow. There are also completely new targets that act through various mechanisms, such as inhibiting metabolism in the tumor microenvironment, he adds.


Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses new targets in melanoma.

In the treatment of patients with melanoma, well known targets such as CTLA4 and PD-1 have been at the forefront of research. Ipilimumab (Yervoy) has been shown to successfully target CTLA-4, while pembrolizumab (Keytruda) and nivolumab (Opdivo) target PD-1. But, Postow says that new immunotherapy targets are emerging in 2018.

IDO and LAG-3 both have very interesting emerging data in melanoma, says Postow. There are also completely new targets that act through various mechanisms, such as inhibiting metabolism in the tumor microenvironment, he adds.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 28, 20182.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x